What role do PROTACs play in targeting tau? PROTACs are bifunctional molecules that recruit E3 ubiquitin ligases to mark tau for proteasomal degradation. They can act sub-stoichiometrically and do not necessarily require sustained target occupancy, but tau degradation remains technically challenging, particularly for CNS disease and aggregated tau species. Radioligand binding and autoradiography are essential for characterising warhead engagement on human brain tissue.

Tau remains a major therapeutic target in neurodegeneration. The severity and distribution of tau pathology, rather than amyloid plaques, correlates most closely with cognitive decline and neuronal loss. Braak staging of neurofibrillary tangle progression remains one of the strongest neuropathological frameworks in Alzheimer disease (AD). The difficulty is that tau is intrinsically disordered, lacks a conventional druggable pocket, and exists in different conformational strains across tauopathies.

The PROTAC Mechanism

PROTACs have three parts: a warhead that binds the protein of interest, a ligand that recruits an E3 ubiquitin ligase, and a linker connecting the two. The PROTAC brings the target and E3 ligase together, forming a ternary complex that drives ubiquitination and proteasomal degradation. Because one PROTAC molecule can degrade more than one copy of the target protein, sustained high affinity occupancy is not always required.

Silva et al. (2019) developed QC-01-175, a CRBN-recruiting PROTAC built on the flortaucipir (T807) scaffold. In iPSC-derived neurons from FTD-spectrum patients carrying the tau-A152T risk variant or the P301L mutation, QC-01-175 cleared both mutant and wild-type tau in a concentration-dependent manner, while having minimal effect on tau in neurons from healthy controls. The selectivity is for disease-associated tau conformations rather than mutant tau per se. Wang et al. (2021) reported C004019, a VHL-recruiting PROTAC that reduced soluble and phosphorylated tau in HEK293-hTau cells and improved cognition in 3xTg-AD mice. Dual-target degradation strategies aimed at both tau and alpha-synuclein aggregates are also being explored, although this remains an emerging area rather than an established therapeutic class.

Molecular Glues and Autophagy-Targeting Chimeras

Molecular glues stabilise a new interaction between the target and an E3 ligase without needing a bifunctional linker. Their smaller size may help developability and CNS exposure compared with many bifunctional degraders, although brain penetration is still compound-specific and cannot be assumed. Autophagy-targeting chimeras (AUTACs and ATTECs) bypass the proteasome entirely, directing targets to lysosomes via the autophagy pathway. This is particularly relevant for aggregated tau species that may not be well suited to proteasomal degradation.

Why Binding Assays and Autoradiography Are Essential for TPD

For any tau TPD programme, the first question is simple: does the warhead engage the relevant tau species in the relevant tissue? Radioligand binding on human post-mortem brain homogenates gives affinity data (K_D, B_max) in the context of real disease pathology. Competition binding then ranks novel warheads against established PET tracers such as flortaucipir, [¹⁸F]MK-6240, or [¹⁸F]PI-2620.

For tau, I would be cautious about any degrader claim that has only been shown in a clean cell system. The tissue engagement data need to come first.

Autoradiography maps where a compound engages neurofibrillary tangles across cortical layers, hippocampal subfields, and white matter, providing spatial resolution that homogenate binding cannot. On neuropathologically confirmed tissue from AD, progressive supranuclear palsy, corticobasal degeneration, and Pick disease, autoradiography reveals conformational selectivity; different tauopathies harbour structurally distinct tau filament folds.

For antibody-based tau therapeutics, autoradiographic target engagement studies using custom [¹²⁵I]iodinated antibodies visualise binding distribution across brain regions, confirming target accessibility.

Translational Challenges

Blood-brain barrier penetration is a major hurdle for PROTACs, whose molecular weights typically exceed 700 Da. Demonstrating warhead engagement in brain tissue, not just cell lines, requires binding and autoradiography data from native preparations. Species differences in tau isoform expression matter: adult rodent brain expresses predominantly 4R tau isoforms, whereas adult human brain expresses both 3R and 4R isoforms in roughly equal proportion. Human tissue binding data are therefore essential before extrapolating from rodent models, particularly for tauopathies whose filament composition is 3R-only, 4R-only, or mixed 3R+4R.

Tau conformational selectivity is another critical consideration. Cryo-EM studies have revealed that the filament structures in AD (paired helical filaments and straight filaments) differ from those in PSP, CBD, and Pick disease. A warhead that binds AD-type aggregates with high affinity may show reduced engagement with PSP-type filaments. Competition autoradiography on neuropathologically characterised tissue from multiple tauopathies maps this selectivity, informing which patient populations a therapeutic is most likely to benefit.

The tau PET tracer field illustrates this point. Flortaucipir was approved for AD imaging but shows variable performance in non-AD tauopathies due to off-target binding at MAO enzymes and lower affinity for non-AD tau conformations. Next-generation tracers such as [¹⁸F]MK-6240 and [¹⁸F]PI-2620 aim to address these limitations, but each has a distinct binding profile on post-mortem tissue. Autoradiographic head-to-head comparisons on the same tissue sections are essential for understanding where each tracer, and by extension each PROTAC warhead, engages the target.

The Clinical Pipeline and Beyond

The tau therapeutic pipeline goes well beyond PROTACs. Anti-tau antibodies (semorinemab, bepranemab, E2814) are in clinical trials targeting different tau epitopes and conformational states. Antisense oligonucleotides such as BIIB080 reduce MAPT mRNA to lower total tau production. For each approach, the same core question remains: does the molecule engage its target in the right tissue, at the right disease stage, with enough selectivity? Binding assays and autoradiography help answer that directly.

How Gifford Bioscience Supports Tau Programmes

At Gifford Bioscience, we provide radioligand binding on human brain homogenates from neuropathologically confirmed tissue, large-section autoradiography across multiple brain regions and tauopathy subtypes, competition binding between novel warheads and PET tracer compounds, custom [¹²⁵I]iodination of therapeutic antibodies for target engagement mapping, and SPR-based screening for fragment and small molecule hit identification.

To discuss how Gifford Bioscience can support your programme, visit www.giffordbioscience.com or contact us at info@giffordbioscience.com.

Frequently Asked Questions

What is a tau PROTAC?

A tau PROTAC is a bifunctional molecule designed to bind tau protein while recruiting an E3 ubiquitin ligase. This brings tau into proximity with the cell’s ubiquitin-proteasome system, marking it for degradation rather than simply blocking its activity.

Why is tau targeted for degradation in Alzheimer disease?

Abnormal accumulation and aggregation of tau protein is closely associated with neuronal damage and cognitive decline in Alzheimer disease and other tauopathies. Targeted protein degradation aims to reduce disease-associated tau rather than relying solely on conventional inhibition or antibody-based approaches.

Why are binding assays important when developing tau PROTACs?

Binding assays help confirm whether the PROTAC warhead engages the intended tau species and determine its affinity and selectivity. Radioligand binding using human brain tissue can be particularly valuable because tau conformation and isoform expression can differ between disease types and experimental models.

How does autoradiography support tau drug development?

Autoradiography shows where a radiolabelled compound binds within brain tissue. In tau programmes, it can help assess engagement with neurofibrillary tangles across different brain regions and compare binding between Alzheimer disease and other tauopathies such as PSP, CBD and Pick disease.

What is the difference between PROTACs and molecular glues?

PROTACs typically contain a target-binding warhead, a linker and an E3 ligase-binding ligand. Molecular glues are generally smaller molecules that promote or stabilise an interaction between a target protein and an E3 ligase without requiring a bifunctional linker. Both approaches can be used to trigger targeted protein degradation.

References

Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239-259.
Sakamoto KM, et al. Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proc Natl Acad Sci USA. 2001;98(15):8554-8559.
Silva MC, et al. Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models. eLife. 2019;8:e45457.
Wang W, et al. A novel small-molecule PROTAC selectively promotes tau clearance to improve cognitive functions in Alzheimer-like models. Theranostics. 2021;11(11):5279-5295.
Goedert M, Eisenberg DS, Crowther RA. Propagation of tau aggregates and neurodegeneration. Annu Rev Neurosci. 2017;40:189-210.
Boxer AL, Sperling R. Accelerating Alzheimer’s therapeutic development: the past and future of clinical trials. Cell. 2023;186(22):4757-4772.
Pettinari A, Uliassi E, Bolognesi ML. Targeting tau protein with proximity inducing modulators. ACS Pharmacol Transl Sci. 2025;8(3):654-672.
Wang X, et al. Tau degradation in Alzheimer’s disease: mechanisms and therapeutic opportunities. Alzheimers Dement. 2025;21:e70048. doi:10.1002/alz.70048.
Pike A, et al. Lessons learned in linking PROTACs from discovery to the clinic. Nat Rev Chem. 2025; doi:10.1038/s41570-025-00784-6.

Tau Pathology and Targeted Protein Degradation: How Binding Assays Support Neurodegeneration Therapeutics